Barotrauma and its complications in COVID-19 patients: a retrospective study at tertiary care hospital of Eastern India

Roopak Dubey1*, Kamal Kumar Sen1 and Aparajita Mishra2

Abstract
Background: The development of barotrauma in COVID-19 patients who were ventilated and admitted to the intensive treatment unit seemed to have been a problematic issue in the COVID era. This study aimed to explore the possibility of developing the barotrauma-related issues with mechanical ventilation in the cases of individuals suffering from COVID-19.

Results: Out of 48 patients who developed barotrauma, 30 (62.5%) presented with pneumothorax, 22 (45.8%) with pneumomediastinum, 10 (20.8%) with subcutaneous emphysema, and 2 (4.1%) with pneumopericardium. Of those that developed barotrauma, 45 (93.7%) patients were in acute respiratory distress syndrome. In patients with and without barotrauma, significant factors were white blood cell count (p = 0.001), neutrophil percentage (p = 0.012), and lymphocyte percentage (p = 0.014). There were no statistically significant differences in CRP, procalcitonin, d-dimer test, LDH, or ferritin.

Conclusions: Patients infected with COVID-19 have a high risk of barotrauma when on mechanical ventilation. As a result, the death rate in this patient group is higher.

Keywords: Pneumothorax, Pneumomediastinum, Subcutaneous emphysema, Respiratory distress syndrome, COVID-19 cases

Background
COVID-19, a novel coronavirus, has spread around the world (World Health Organization 2. WHO Director-General's remarks at the media briefing 2020). This highly transmissible and contagious disease affects a variety of systems, including the respiratory tract. In COVID-19 patients in the intensive care unit (ICU), pneumothorax is reported to occur at a rate of 2% (World Health Organization 2. WHO Director-General's remarks at the media briefing 2020; Chan et al. 2020 Feb 15). Recent studies have found that barotrauma-related issues caused by invasive mechanical ventilation are becoming increasingly prevalent, with up to 15% of COVID-19 patients experiencing them (Bajema et al. 2020 Feb 14). In mechanically ventilated patients, the relationship between acute respiratory distress syndrome (ARDS) and subsequent pneumothorax has long been recognised as a risk factor for fatality (Huang et al. 2020 Feb 15; Chen et al. 2020 Feb 15; Wang et al. 2020 Mar 17).

Patients with ARDS and COVID can benefit from positive pressure ventilation (PPV), which is a non-physiological and invasive/non-invasive approach that can save their lives. It has its own set of hazards and consequences, including pulmonary barotrauma (PBT) and ventilator-induced lung injury, both of which have been related to multisystem organ failure in ARDS patients (Slutsky and Ranieri 2013 Nov 28).
Using a low tidal volume (Vt) and a high positive end-expiratory pressure (PEEP) in patients with ARDS has been shown in several trials to minimise hospital mortality (Walkey et al. 2017). Low Vt (4–8 mL/kg) is suggested by numerous standards, including the COVID-19 guidelines from the last surviving sepsis campaign, since it is considered to decrease volutrauma in ARDS patients’ lungs (Alhazzani et al. 2021 Mar 1; Goligher et al. 2017; Levy et al. 2018 Jun). Limiting lung damage to plateau pressures (Pplat) of less than 30 cm H2O is another lung-protective strategy, since Pplat>32 has been associated with higher short-term mortality (Yasuda et al. 2017 May 1). During the COVID pandemic, extrinsic PEEP has been utilised in ARDS to improve oxygenation, lower oxygen demand (FiO2), and minimise atelectrauma (repeated opening and closing of alveoli), all of which helped to prevent ventilator-induced lung damage (Alhazzani et al. 2021 Mar 1). In trials, higher PEEP techniques have been shown to improve survival in ARDS patients at the expense of an increased risk of pneumothorax (Briel et al. 2010 Mar 3). To ensure adequate oxygenation, PEEP might be raised at the risk of increased Pplat and barotrauma.

In mechanical ventilation, PBT refers to alveolar rupture caused by increased transalveolar pressure (the alveolar pressure minus the pressure in the adjacent interstitial space), which causes air leaks into extra-alveolar tissue, resulting in pneumothorax, pneumomediastinum, pneumoperitoneum, and subcutaneous emphysema (Udi et al. 2021 Apr). These patients frequently require a high level of PEEP to maintain oxygenation, putting them at risk for barotrauma.

The objective of our study was to identify clinical features and risk factors associated with the development of barotrauma in COVID-19 patients who were mechanically ventilated. The goal of the study was to see how COVID-19 affects the clinical course and prognosis of barotrauma-related ailments.

**Methods**

**Design of the study and data gathering**

Between March 2021 and June 2021, a retrospective research was conducted at the Kalinga Institute of Medical Sciences in India. The hospital’s institutional ethics committee granted clearance for the project. The ethics committee approved a waiver of consent from individual patients due to the retrospective nature of the study.

A total of 350 patients were evaluated after reverse transcriptase polymerase chain reaction (RT-PCR) nasal swab tests revealed that they had COVID-19 infection and were sent to the hospital’s intensive care unit (ICU) for mechanical ventilation. All patients who developed PBT (pneumothorax, pneumomediastinum, pneumopericardium, or subcutaneous emphysema) and received any form of PPV, including non-invasive positive pressure ventilation (NIPPV) such as continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) and those who required invasive positive pressure ventilation (IPPV), were included.

Individuals having a pre-existing pneumothorax at the time of admission, as well as those with identified iatrogenic pneumothorax episodes, were excluded.

Clinical data were obtained retrospectively by looking through the medical records of the patients. The hospital database was used to get information such as age, sex, chronic medical conditions, and history of underlying lung disease, as well as presenting symptoms, laboratory values on admission, and outcomes (death or discharge).

**Ventilation protocol**

All IPPV patients were treated with lung-protective ventilation strategies that included a low tidal volume (Vt) of 4–8 mL/kg predicted body weight, a volume-limited assist control mode, and an initial positive end-expiratory pressure (PEEP) of 5 cm H2O that was gradually increased to improve oxygenation while aiming for a plateau pressure (Pplat) of 30 cm H2O to avoid lung injury. According to our hospital’s sedative and muscle relaxant protocol, benzo-diazepines infusions were used in patients with ARDS in combination with a powerful analgesic such as fentanyl or morphine. Patients who were getting IPPV should follow this sedative regimen. Patients who received NIPPV, on the other hand, were not given sedatives or analgesics and were only given minimal dosages as needed for comfort.

**Data analysis**

HRCT chest imaging/X-rays were used to radiologically identify PBT. An ICU posted radiologist analysed and evaluated HRCT data and chest X-rays.

All of the data were examined using SPSS (IBM, version 25). For continuous data, descriptive statistics were used to calculate mean and standard deviations, whereas frequency statistics were employed to create numbers and percentages for categorical variables. The statistical significance was determined using a p value of less than 5%.

**Results**

The 350 patients in the study had an average age of 55.9 (13.5) years, with 270 (77.14%) of them being male. Data on demographics, clinical care, and biochemistry are shown in Table 1. Throughout their hospital stay, all PPV patients were divided into two groups. The first group included 48/350 (13.7 percent) individuals who acquired PBT after receiving any form of PPV. The second...
group consisted of 302 individuals (86.28%) who had received any type of PPV but had not acquired PBT. Out of 350 patients who received PPV, 190 patients (54.28%) received IPPV, and 30 patients developed PBT. On the other hand, NIPPV was given to 160 patients (45.71 percent). Ninety patients got BiPAP, and 70 patients received CPAP, with 10 and 8 patients developing PBT, respectively, after receiving NIPPV (Fig. 1).

Out of 48 patients who developed barotrauma, 30 (62.5%) presented with pneumothorax, 22 (45.8%) with pneumomediastinum, 10 (20.8%) with subcutaneous emphysema, and 2 (4.1%) with pneumopericardium (Table 2) (Figs. 2 and 3).

In our study, 45 (93.7%) of the total patients \(n = 48\) were suffering from ARDS. At the time of the barotrauma, 30/48 (62.5%) of these patients had severe ARDS (PaO2/ FiO2 of 100), whereas 10/48 (20.83) had moderate ARDS (PaO2/ FiO2 of 100–200) (Table 2).

Several inflammatory markers were shown to be statistically different between people who had barotrauma and those who did not. Significant factors were white blood cell count (WBC) \((p = 0.001)\), neutrophil percentage \((p = 0.012)\), and lymphocyte percentage \((p = 0.014)\) (Table 1). There were no statistically significant differences in CRP, procalcitonin, d-dimer test, lactate dehydrogenase (LDH), or ferritin.

### Table 1

Demographic, clinical, and biochemical characteristics according patients with or without barotrauma

| Characteristics | Barotrauma \((n = 48)\) | No barotrauma \((n = 310)\) | \(p\) value* |
|----------------|-------------------------|-----------------------------|-------------|
| **Demography** |                         |                             |             |
| Age in years (SD) | 55.9 (13.5)              | 56.0 (13.3)                  | 0.12        |
| Males           | 38 (79.1%)               | 220 (70.9%)                 | 0.23        |
| Females         | 10 (20.9%)               | 46 (29.1%)                  | 0.45        |
| **Symptoms**    |                         |                             |             |
| Shortness of breath | 30 (62.5%)             | 210 (67.7%)                | 0.75        |
| Cough           | 24 (50.0%)               | 118 (38.0%)                 | 0.34        |
| Sore throat     | 10 (20.8%)               | 78 (25.1%)                  | 0.56        |
| Hemoptysis      | 5 (10.4%)                | 43 (13.8%)                  | 0.12        |
| Unconsciousness | 26 (54.1%)               | 190 (61.2%)                 | 0.01        |
| **Comorbidities** |                        |                             |             |
| Diabetes        | 10 (20.8%)               | 60 (19.3%)                  | 0.08        |
| Hypertension    | 9 (16.6%)                | 54 (17.5%)                  | 0.12        |
| Asthma          | 7 (12.5%)                | 34 (11.0%)                  | 0.23        |
| COPD            | 3 (6.2%)                 | 20 (6.4%)                   | 0.44        |
| CKD             | 2 (4.1%)                 | 16 (5.1%)                   | 0.09        |
| **Biochemical** |                         |                             |             |
| WBC (SD)        | 12.7 (7.7)               | 8.5 (4.8)                   | 0.001       |
| Neutrophils (SD) | 84.8 (12.4)             | 78.0 (12.9)                 | 0.012       |
| Lymphocytes (SD) | 9.8 (10.5)               | 13.8 (10.1)                 | 0.014       |
| CRP (SD)        | 134.0 (111.4)            | 142.4 (119.6)               | 0.23        |
| Procalcitonin (SD) | 4.3 (12.3)            | 22.2 (242.7)                | 0.10        |
| D-dimer assay (SD) | 2216.2 (391.8)       | 2565.6 (319.5)              | 0.32        |
| LDH (SD)        | 1005.9 (3513.6)          | 732.0 (270.2)               | 0.10        |
| Ferritin (SD)   | 1413.8 (1966.4)          | 1082.8 (1490.1)             | 0.23        |
| Length of Stay, days (SD) | 16.4 (8.5)       | 20.1 (14.0)                 | 0.12        |
| **Pressure**    |                         |                             |             |
| PEEP minimum (SD) | 7.7 (2.6)               | 6.7 (3.8)                   | 0.08        |
| PEEP Maximum (SD) | 14.5 (2.7)              | 12.5 (5.7)                  | 0.002       |
| **Outcome**     |                         |                             |             |
| Deaths          | 35/48 (72.9%)            | 120/302 (39.7%)             | 0.015       |
| Discharged      | 13/48 (27.1%)            | 182/302 (60.2%)             | 0.08        |

Unless otherwise stated, data for continuous variables are provided as means (standard deviations). For categorical variables, data are given as a number (%). The *significance level was set at \(p\) value less than 0.05. Significant \(p\) values have been shown in bold numericals.
All 48 barotrauma patients were mechanically ventilated. Mortality was substantially higher among individuals with barotrauma 35/48 (72.9%) compared to those without barotrauma 120/302 (39.73%) ($p = 0.015$). The maximal PEEP in barotrauma patients was significantly greater than in non-barotrauma patients ($p = 0.002$). There were no significant changes in demographic parameters or length of hospital/ICU stay between patients with and without barotrauma. Despite the fact that the prevalence of comorbidities was not statistically significant in patients with and without barotrauma ($p = 0.57$), the majority of PPV patients had underlying comorbidities, the most common of which were hypertension (HTN) and diabetes.

Table 2 Types of barotrauma and categories of ACUTE respiratory distress syndrome

| Types of barotrauma (n = 48)                          |          |
|------------------------------------------------------|----------|
| Pneumothorax                                          | 30 (62.5%)|
| Pneumomediastinum                                    | 22 (45.8%)|
| Subcutaneous emphysema                                | 10 (20.8%)|
| Pneumopericardium                                     | 2 (4.1%)  |
| Acute respiratory distress syndrome (ARDS) (n = 45/48)|          |
| Mild                                                  | 30/48 (62.5%)|
| Moderate                                              | 10/48 (20.8%)|
| Severe                                                | 5/48 (10.4%)|

Fig. 1 Distribution of patients admitted in our hospital from March to June 2021
mellitus (DM). All of the patients on mechanical ventilation were managed with lung-protective measures. A tube thoracostomy was placed at the bedside of patients who suffered a pneumothorax.

The characteristics of patients who received IPPV versus NIPPV were compared in a sub-analysis. IPPV-treated patients had a higher death rate ($p = 0.003$).

Six people in our research showed symptoms of barotrauma before starting mechanical breathing (findings of pneumomediastinum, subcutaneous emphysema, or both). To maintain track of these people, clinical examinations and serial chest X-rays were employed.

Besides established complications like pneumothorax, pneumomediastinum, and subcutaneous emphysema, few other findings like cystic bronchiectasis and cavitary lesions were also seen in patients admitted in ICU with PPV. Three of the 48 patients had fungal development in their pre-existing cavities. Two of them were attributable to candida species, while one was due to mucor infection, according to fungal culture test (Fig. 4).

**Discussion**

The present study focused at COVID-19 patients and looked at risk factors for barotrauma as well as clinical consequences for management. COVID-19 patients suffer from barotrauma, which has been thoroughly documented in the literature (Abdallat et al. 2020; McGuinness et al. 2020 Nov). In our single-centre investigation, the incidence of barotrauma-related issues in COVID-19 patients was 13.7 percent, which is virtually identical to the rate described by McGuinness et al. (McGuinness et al. 2020 Nov).

Pre-existing lung disease and the development of barotrauma during invasive ventilation administration have been highlighted in several additional reports. Pneumonia, chronic obstructive pulmonary disease (COPD), and lung cancer, in particular, have all been shown to increase the risk of barotrauma (McGuinness et al. 2020 Nov). Similarly, all of the patients with barotrauma in the current research ($n = 48$) had COVID-19 pneumonia, 12.5 percent had asthma, and 6.2 percent had a history of COPD.
Total 350 patients were provided mechanical ventilation in our research, and 13.7 percent \((n = 48)\) of them had barotrauma, which was radiologically confirmed as a pneumothorax, pneumomediastinum, or surgical emphysema. PBT was found in 10–14 percent of COVID-19-infected mechanically ventilated ARDS patients in many case series researches, which mirrored our findings (McGuinness et al. 2020 Nov; Lemmers et al. 2020; Capaccione et al. 2021 Feb; Edwards et al. 2021 Jan 1). Martinelli et al. found that around 25% of intubated patients acquired pneumothorax or pneumomediastinum, which is higher than the incidence (13.7%) identified in our group (Martinelli et al. 2020).

In terms of biochemical results, we discovered that patients who experienced barotrauma had higher WBC, neutrophil counts, and LDH. These findings are comparable to those of Shioe et al., who observed that patients infected with the SARS-CoV virus had greater levels of LDH and neutrophils, which were likewise linked to a higher degree of lung damage. However, in that study, the
findings were not compared to those of individuals who did not experience barotrauma (Siho et al. 2004 Jun 1).

When invasive ventilation is utilised, ARDS has been established as an independent risk factor for barotrauma. In the literature, the incidence of ARDS has been reported to fluctuate, with some studies showing rates as high as 15% (Gammon et al. 1992 Aug 1; Eisner et al. 2002; Gammon et al. 1995 Oct; Weg et al. 1998 Feb 5; Acute Respiratory Distress Syndrome Network 2000 May 4). In our study, 45 (93.75%) of the 48 patients who had barotrauma satisfied the ARDS criterion.

Furthermore, in our study, patients who had barotrauma had a higher maximum PEEP than patients who did not develop barotrauma ($p=0.002$). High PEEP has been frequently employed as part of a ventilator management approach. This has been linked to barotrauma, which necessitates thoracostomy drainage in certain cases. This condition can induce serious hemodynamic alterations and is linked to a greater death risk in these individuals.

To decrease barotraumatic occurrences in COVID-19, low tidal volumes (4–8 ml/kg) and plateau pressures (Pplat) of less than 30 cm H2O should be used in practise. However, in some cases, a patient may require greater PEEP to achieve adequate oxygenation, which may raise the risk of higher Pplat and barotrauma. As a result, when more PEEP is administered, doctors must calculate the risk vs. benefit ratio.

High PEEP, high tidal volumes, and high plateau pressures are the main variables which increase the occurrence of barotraumatic events.

In our study, six people had spontaneous pneumomediastinum or pneumothorax. Similar case reports from China described spontaneous pneumomediastinum in COVID-19 patients (Eisner et al. 2002). Before starting mechanical ventilation, these patients experienced spontaneous pneumomediastinum or pneumothorax, which might suggest a severe kind of lung injury associated with COVID-19 infection.

Three patients with pneumothorax and/or pneumomediastinum were found to have cavity lesions in the lung parenchyma, which demonstrated fungal growth on culture. These cavities might be pre-existing as a result of PPV-induced barotrauma, or they could be developed by invasive fungal infections on their own. But definitely, mechanical ventilation could be a contributing factor in the development of these cavities, which could be exacerbated by fungus infection. The radiologists play an important role in detecting barotraumatic events (like pneumothorax, pneumomediastinum, subcutaneous emphysema, and pneumopericardium) in COVID patients as these patients undergo HRCT or X-ray chest at least once in their course of disease.

In line with the findings of De Lassence et al., our investigation found that patients who acquired barotrauma had a substantially higher death rate (72.9%) than patients (39.73%) who did not develop barotrauma ($p=0.015$) (Lassence et al. 2006 Jan 1). It is worth noting that the mortality rate was also substantial among patients who did not have barotrauma-related events; this might reflect a morbid cohort of ICU patients.

Conclusions

In COVID-19 patients who are mechanically ventilated, there is a substantial risk of barotrauma. COVID-19 is, in fact, a risk factor for the development of spontaneous pneumothorax and/or pneumomediastinum, as demonstrated by the presence of these conditions in 6 of our sample members. In our patient sample, we discovered many variables that have been associated with the development of barotrauma-related sequelae. It is a delicate balancing act to find the optimal ventilator settings for lung recruitment while avoiding barotrauma. COVID-19 patients who had barotrauma had a significant mortality rate, according to our findings. The role of radiologist is important in the early detection of barotrauma and may be able to aid in the treatment of its complications.

Abbreviations

ARDS: Acute respiratory distress syndrome; ICU: Intensive care unit; PPV: Positive pressure ventilation; PBT: Pulmonary barotrauma; VT: Tidal volume; PEEP: Positive end-expiratory pressure; Pplat: Plateau pressures; RTPCR: Reverse transcriptase polymerase chain reaction; NIPPV: Non-invasive positive pressure ventilation; CPAP: Continuous positive airway pressure; BiPAP: Bi-level positive airway pressure; IPPV: Invasive positive pressure ventilation; DM: Diabetes mellitus; HTN: Hypertension; COPD: Chronic obstructive pulmonary disease; WBC: White blood counts; LDH: Lactate dehydrogenase.

Acknowledgements

Nil.

Author contributions

KKS contributed to manuscript formation, RD and SSM were involved in data analysis, and JK, AM, and SSM contributed to data collection. All authors have read and approved the manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Ethical committee clearance has been taken for research purpose. Name of Ethics committee—Institutional Ethics Committee, Kalinga Institute of Medical Sciences. The hospital institutional ethics committee granted clearance for the project. The ethics committee approved a waiver of consent from individual patients due to the retrospective nature of the study.
Consent for publication
The ethics committee approved a waiver of consent from individual patients due to the retrospective nature of the study.

Competing interest
Nil.

Author details
1Department of Radiodiagnosis, Kalinga Institute of Medical Sciences Bhubaneswar, Bhubaneswar, Odisha, India. 2Department of Community Medicine, Kalinga Institute of Medical Sciences Bhubaneswar, Bhubaneswar, Odisha, India.

Received: 18 August 2021  Accepted: 25 June 2022
Published online: 15 July 2022

References
Abdallat M, Khalil M, Al-Awova G, Kootheru R, Punzina C (2020) Barotrauma in COVID-19 patients. J Lung Health Dis 4(2):8–12. https://doi.org/10.29245/2689-999X/2020/2.1163

Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342(18):1301–1308

Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC et al. (2021) Incidence of barotrauma in patients with COVID-19 pneumonia during prolonged invasive mechanical ventilation: a case-control study. J Intensive Care Med 36(4):212–2136

Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC et al. (2021) Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med 49(3):e219–e234

Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC et al. (2020) Persons evaluated for 2019 novel coronavirus—United States, January 2020. Morb Mortal Wkly Rep 69(6):166

Briel M, Meade M, Mercart A, Brower RG, Talmor D, Walter SD et al. (2010) Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 303(9):865–873

Capaccione KM, D’oouza B, Leb J, Luk L, Duong J, Tsai WY et al. (2021) Pneumothorax rate in intubated patients with COVID-19. Acute Crit Care 36(1):81

Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–523

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513

de Lassence A, Timsit JF, Tafflet M, Azoulay E, Jamali S, Vincent F et al. (2006) Severe acute respiratory syndrome complicated by spontaneous pneumothorax. Chest 125(6):2345–2351

Dubre J, Lang CN, Zlotzmann V, Krueger K, Fluegler A, Bamberger F et al. (2021) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069

Gammon RB, Shin MS, Groves RH Jr, Hardin JM, Hsui C, Bucbahr SE (1995) Clinical risk factors for pulmonary barotrauma: a multivariate analysis. Am J Respir Crit Care Med 152(4):1235–1240

Gammon RB, Shin MS, Groves RH Jr, Hardin JM, Hsui C, Bucbahr SE (1995) Pulmonary barotrauma in mechanically ventilated patients with COVID-19 pneumonia during prolonged invasive mechanical ventilation: a case-control study. Am J Med 135(1):97–82

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395(10223):497–506

McGuinness G, Zhan C, Rosenberg N, Azouir L, Wickstrom M, Mason DM et al. (2020) Increased incidence of barotrauma in patients with COVID-19 on invasive mechanical ventilation. Radiology 297(2):E252–E262

Sihoe AD, Wong RH, Lee AT, Lau LS, Leung NY, Law Ki et al. (2004) Severe acute respiratory syndrome complicated by spontaneous pneumothorax. Chest 125(6):2345–2351

Slutsky AS, Ranieri VM (2013) Ventilator-induced lung injury. N Engl J Med 369(22):2126–2136

Walker A, Goligher EC, Del Sorbo L, Hodgson CL, Adhikari NK, Wunsch H (2017) Low Tidal volume versus non—–volume-limited strategies for patients with acute respiratory distress syndrome A systematic review and meta-analysis. Annals Am Thorac Soc 14(Supplement_4):S271–S279.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069

World Health Organization 2. WHO Director-General’s remarks at the media briefing on 11 February 2020

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com